Biofrontera Inc. (BFRIW)
Biofrontera Statistics
Share Statistics
Biofrontera has 86.63M shares outstanding. The number of shares has increased by -20.82% in one year.
| Shares Outstanding | 86.63M |
| Shares Change (YoY) | -20.82% |
| Shares Change (QoQ) | -61.19% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 71.57M |
| Failed to Deliver (FTD) Shares | 100 |
| FTD / Avg. Volume | 0.68% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -0.21 and the forward PE ratio is null. Biofrontera's PEG ratio is 0.
| PE Ratio | -0.21 |
| Forward PE | n/a |
| PS Ratio | 0.13 |
| Forward PS | 0.1 |
| PB Ratio | 0.89 |
| P/FCF Ratio | -0.17 |
| PEG Ratio | 0 |
Enterprise Valuation
Biofrontera Inc. has an Enterprise Value (EV) of 8.34M.
| EV / Earnings | -0.41 |
| EV / Sales | 0.24 |
| EV / EBITDA | -0.45 |
| EV / EBIT | -0.37 |
| EV / FCF | -0.33 |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 1.13.
| Current Ratio | 1.28 |
| Quick Ratio | 0.67 |
| Debt / Equity | 1.13 |
| Total Debt / Capitalization | 52.97 |
| Cash Flow / Debt | -4.61 |
| Interest Coverage | -37.8 |
Financial Efficiency
Return on equity (ROE) is -4.2% and return on capital (ROIC) is -222.65%.
| Return on Equity (ROE) | -4.2% |
| Return on Assets (ROA) | -0.72% |
| Return on Capital (ROIC) | -222.65% |
| Revenue Per Employee | $410,493.98 |
| Profits Per Employee | $-242,542.17 |
| Employee Count | 83 |
| Asset Turnover | 1.22 |
| Inventory Turnover | 1.6 |
Taxes
| Income Tax | 14K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 99.56% in the last 52 weeks. The beta is 0.3, so Biofrontera's price volatility has been higher than the market average.
| Beta | 0.3 |
| 52-Week Price Change | 99.56% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 47.19 |
| Average Volume (20 Days) | 14.64K |
Income Statement
In the last 12 months, Biofrontera had revenue of 34.07M and earned -20.13M in profits. Earnings per share was -13.02.
| Revenue | 34.07M |
| Gross Profit | 16.63M |
| Operating Income | -22.68M |
| Net Income | -20.13M |
| EBITDA | -18.45M |
| EBIT | -22.68M |
| Earnings Per Share (EPS) | -13.02 |
Balance Sheet
The company has 1.34M in cash and 5.4M in debt, giving a net cash position of -4.06M.
| Cash & Cash Equivalents | 1.34M |
| Total Debt | 5.4M |
| Net Cash | -4.06M |
| Retained Earnings | -99.65M |
| Total Assets | 18.52M |
| Working Capital | 5.9M |
Cash Flow
In the last 12 months, operating cash flow was -24.89M and capital expenditures -5K, giving a free cash flow of -24.9M.
| Operating Cash Flow | -24.89M |
| Capital Expenditures | -5K |
| Free Cash Flow | -24.9M |
| FCF Per Share | -16.1 |
Margins
Gross margin is 48.8%, with operating and profit margins of -66.56% and -59.09%.
| Gross Margin | 48.8% |
| Operating Margin | -66.56% |
| Pretax Margin | -59.04% |
| Profit Margin | -59.09% |
| EBITDA Margin | -54.16% |
| EBIT Margin | -66.56% |
| FCF Margin | -73.08% |
Dividends & Yields
BFRIW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -18600% |
| FCF Yield | -410.59% |
Analyst Forecast
Currently there are no analyst rating for BFRIW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -7.97 |
| Piotroski F-Score | 2 |